Abrocitinib Taiwan Treatment Pattern and Real World Study in ATopiC Dermatitis (ATTRACT Registry)
← catalyst calendarSponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
—
Status
Completed
Study type
Observational
Enrollment
41actual
Sites
8
Country
Taiwan
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-06-19 | actual | When the study began enrolling |
| Primary completion | 2026-06-22 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-06-22 | actual | The whole study's end, after follow-up |
| First posted | 2024-04-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Dermatitis, Atopic
- Dermatitis
- Eczema
- Skin Diseases
- Immune System Diseases
- Janus Kinase Inhibitors
Primary outcomes
what the primary-completion date above is the date OFPercentage of Participants Achieving >= 75% Improvement From Baseline in Eczema Area and Severity Index (EASI-75) Response at Week 2, 12, 52
measured Week 2, 12, 52
Percentage of Participants Achieving >= 90% Improvement From Baseline in Eczema Area and Severity Index (EASI-90) Response at Week 2, 12, 52
measured Week 2, 12, 52
Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response of Clear (0) or Almost Clear (1) and Greater Than or Equal to 2 Points Improvement From Baseline at Week 2, 12, 52
measured Week 2, 12, 52
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed